SARASOTA, FL -- (MARKET WIRE) -- November 21, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that its German business partner, Biofrontera AG, in which the Company owns an approximate 10% stake, has received authorization to begin its first human study of its BF-1 drug, which is intended to prevent migraine headaches.
